Overview Initiation of Insulin Aspart in Type 2 Diabetes Status: Completed Trial end date: 2004-02-02 Target enrollment: Participant gender: Summary This trial is conducted in Europe. The aim of this trial is to investigate if using insulin aspart as start therapy will improve the efficacy on daytime blood glucose cycle profile in subjects with type 2 diabetes. Phase: Phase 4 Details Lead Sponsor: Novo Nordisk A/STreatments: InsulinInsulin AspartInsulin degludec, insulin aspart drug combinationInsulin, Globin ZincInsulin, Long-Acting